Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
2 min synopsisUK scopeSources checked 13 Sept 2026Clinical review pending
Saved on this device
!
Neurological MSCC
New weakness, sensory loss, gait failure or bladder and bowel dysfunction in a person with cancer can progress to permanent paralysis and is an oncological and spinal emergency.
Action: Contact the MSCC coordinator immediately, give dexamethasone 16 mg orally or equivalent parenterally as soon as possible, arrange whole-spine MRI as soon as possible and within 24 hours, and plan surgery or radiotherapy without waiting for steroid response.
Synopsis
Prescribe dexamethasone safely for metastatic spinal cord compression, preserve urgent imaging and definitive treatment, and handle exclusion, haematological malignancy and withdrawal correctly.
This dexamethasone regimen belongs to metastatic spinal cord compression and direct malignant spinal infiltration; it is not a generic treatment for disc, trauma, epidural abscess or haematoma.
For neurological symptoms or signs of MSCC, NICE says offer 16 mg oral dexamethasone or equivalent parenteral dose as soon as possible, then continue 16 mg daily while awaiting surgery or radiotherapy.
The worked case keeps the medication, urgent whole-spine MRI and definitive-treatment sequence visible in Rapid; steroids are a bridge, not decompression.
Key red flags
Neurological symptoms or signs with suspected MSCC trigger immediate dexamethasone and MRI; pain improvement after a dose does not remove compression.
Rapidly progressive weakness, loss of walking, sphincter dysfunction or an unstable painful spine requires immediate coordinator and spinal-team escalation.
Radiologically suspected lymphoma or myeloma without neurological symptoms needs specialist haematology advice before steroids because tissue diagnosis and tumour appearance may be affected.
Hyperglycaemia, infection, delirium, gastrointestinal bleeding, proximal weakness or psychiatric change can emerge during corticosteroid therapy and require active surveillance.
Neurological MSCC
Cancer plus new limb weakness, gait disturbance, sensory loss, radicular pain or bladder and bowel dysfunction warrants emergency treatment and imaging.
Spinal instability
Mechanical pain on movement, progressive deformity, collapse or severe load-related pain may make mobilisation hazardous and requires stability assessment.
Reasoning priorities
01
Whole-spine MRI within 24 hours
Confirm MSCC, identify additional levels, define cord or cauda compression and guide surgery or radiotherapy.
Obtain as soon as possible in neurological MSCC. A positive scan defines anatomy; a negative scan should prompt stopping short empirical dexamethasone and evaluating alternatives.
Worked reasoning
Worked caseCancer with new leg weakness
An adult with known cancer develops a sensory level and progressive bilateral weakness over hours.
Context: contact the MSCC coordinator, establish time of neurological change, examine power, sensation, gait and sphincters, assess stability and protect movement if instability is suspected.
Reasoning: recognise neurological MSCC and offer dexamethasone 16 mg orally or equivalent parenteral dose immediately; arrange whole-spine MRI as soon as possible and within 24 hours.
Outcome: continue 16 mg daily while awaiting urgent surgery or radiotherapy, monitor glucose, give PPI acid suppression and do not allow symptomatic response to delay definitive therapy.
Verification: after surgery or when radiotherapy begins, reduce dexamethasone gradually; track neurological function, pain, glucose, infection, gastrointestinal harm and withdrawal during the taper.
Key medicines
Dexamethasone for neurological MSCCOffer 16 mg orally, or an equivalent parenteral dose, as soon as possible; after the initial dose continue 16 mg orally or equivalent parenterally once daily while awaiting surgery or radiotherapy.Monitor blood glucose and infection, offer proton-pump-inhibitor acid suppression, and review psychiatric, gastrointestinal and proximal-muscle effects. Do not import this dose into non-malignant compression.
Proton-pump inhibitor acid suppressionOffer an age-appropriate formulary PPI at the standard gastroprotection dose while corticosteroid treatment continues; select agent and route from interactions, swallowing and local formulary.Review renal, electrolyte, infection and interaction risks and stop when gastroprotection is no longer indicated; a PPI does not make extreme steroid doses safe.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 13 Sept 2026; clinical approval remains outstanding.
NICE NG234 spinal metastases and MSCCNICE NG234, published 6 September 2023 and last reviewed 19 March 2026; recommendations on recognition, immobilisation, MRI, corticosteroids, radiotherapy, invasive interventions and rehabilitation read 13 September 2026. Applies to spinal metastases, direct malignant infiltration and metastatic spinal cord compression. Chapter-specific use: steroids in malignant cord compression.
NICE NG234 corticosteroid evidence reviewNICE evidence review J underpinning NG234 recommendations 1.8.1–1.8.7, published 2023; evidence tables, benefits, adverse effects, haematological-malignancy discussion, glucose and gastric protection read 13 September 2026. Evidence is limited and does not support extreme loading-dose extrapolation. Chapter-specific use: steroids in malignant cord compression.
NICE NG243 adrenal insufficiency guidelineNICE NG243 adrenal insufficiency identification and management, published 28 August 2024; glucocorticoid withdrawal principles read 13 September 2026. Used only for the dependency of prolonged-course tapering; it does not determine the acute MSCC dexamethasone indication. Chapter-specific use: steroids in malignant cord compression.